HIF1A and B-cell chronic lymphocytic leukemia: Intriguingly, HIF-1α was stimulated and activated in MSCs treated by CLL-derived microvesicles, leading to increased production of vascular endothelial growth factor (VEGF) and modified microenvironment in favor of CLL survival and resistance to chemotherapy [88].